Type 2 & other diabetes

Comprehensive CMR evaluation including 4D flow-derived E/A vorticity ratio in overweight adults with and without type 2 diabetes mellitus

Cardiovasc DiabetolPublished Cross-sectional study

Authors' conclusion

The present study suggests that the 4D flow CMR-derived E/A vorticity ratio may serve as a potential LV diastolic biomarker, given its capability in differentiating T2D-specific changes and stronger associations with clinical measures as well as CMR and echocardiographic parameters.

Study context

Population
Middle-aged participants: lean, overweight without T2D and overweight with uncomplicated T2D
Participants
13 / 37 / 28
Exposure
Lean individuals vs overweight controls without T2D vs overweight individuals with uncomplicated T2D
  • LIn = 13reference
  • CWOn = 37
  • T2Dn = 28
Outcome
4D flow CMR diastolic indices (E/A velocity, flow and vorticity ratios)
Methodological details4D flow CMR, age- and sex-similar groups
  • 4D flow CMR
  • Age- and sex-similar groups

Main finding

As reported in the abstract

  • Between LI and CWO: P = 0.029
  • Between CWO and T2D: P = 0.025
  • Between CWO and T2D: P = 0.031
  • Between CWO and T2D: P = 0.034
  • Holm-Bonferroni correction for pairwise comparisons

Observational data: associations, not effects.

Further findings

OutcomeP value
Cardiorespiratory fitnessCWO vs LI · lower with CWOP < 0.001
Cardiorespiratory fitnessT2D vs LI · lower with T2DP < 0.001

Cardiorespiratory fitness

No difference between CWO and T2D

Correlation of E/A vorticity ratio with echocardiographic MV E/A velocity ratio

Spearman's rho (adjusted for age and sex), 95% CI 0.07-0.60, P = 0.010
0.35

Independent determinants of E/A vorticity ratio (multivariate regression)

Age, β (P = 0.001)
- 0.014
Hypertension, β (P = 0.015)
- 0.130
Heart rate, β (P = 0.001)
- 0.009
Circumferential peak early diastolic strain rate, β (P = 0.002)
0.431

Original publication

Comprehensive CMR evaluation including 4D flow-derived E/A vorticity ratio in overweight adults with and without type 2 diabetes mellitus. Cardiovasc Diabetol. Published 8 December 2025. doi:10.1186/s12933-025-02999-9

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.